Kim DW, Tan E, Zhou JM, Schell MJ, et al. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with
mismatch repair proficient metastatic colorectal cancer. Br J Cancer 2021 Apr 7. pii: 10.1038/s41416-021-01368.
PMID: 33828254